Search

Background: There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies., Case Presentation: Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19 + CD20 + B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies. The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis. The patient subsequently achieved an undetectable viral load, and his pneumonia resolved., Conclusions: Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies., (© 2021. The Author(s).)

Competing Interests: Disclosure JMF-S is President and Founder of PharmaMar, S.A. (Madrid, Spain). JJ holds stocks of Pangae Oncology, has a non-remunerated role in the Scientific Advisory Board and holds stocks of Phosplatin Therapeutics; and is a full-time employee of PharmaMar, S.A. (Madrid, Spain). JAL-M is employee and shareholder of PharmaMar, S.A (Madrid, Spain), and also a co-inventor of a patent for plitidepsin (WO2008135793A1). XELE is employee and shareholder of PharmaMar, S.A (Madrid, Spain). All other authors have declared no conflicts of interest.